Clinical characteristics
| . | All patients(n = 894) . |
|---|---|
| Sex, n (%) | |
| Male | 546 (61.1) |
| Female | 348 (38.9) |
| Age, mean (SD) | 54.93 (12.62) |
| Disease, n (%) | |
| Leukemia | 420 (47.0) |
| Lymphoma | 166 (18.6) |
| MDS/MPN | 199 (22.3) |
| Multiple myeloma | 93 (10.4) |
| Nonmalignant | 16 (1.8) |
| Intensity, n (%) | |
| Ablative | 589 (65.9) |
| Reduced intensity | 191 (21.4) |
| Nonablative | 114 (12.8) |
| Total body irradiation, n (%) | 273 (30.5) |
| Donor match, n (%) | |
| Related haploidentical | 44 (4.9) |
| Related identical | 288 (32.2) |
| Related nonidentical | 4 (0.4) |
| Unrelated identical | 447 (50.0) |
| Unrelated nonidentical | 111 (12.4) |
| Grafts, n (%) | |
| BM | 86 (9.6) |
| PBSCs, | 361 (40.4) |
| PBSCs, CD34+ | 447 (49.9) |
| GVHD (first 100 d), n (%) | 346 (39.8) |
| Grade 0-1 | 628 (70.2) |
| Grade 2-4 | 266 (29.8) |
| Lower gut GVHD | 84 (9.4) |
| Grade 0-1 | 855 (95.6) |
| Grade 2-4 | 39 (4.4) |
| . | All patients(n = 894) . |
|---|---|
| Sex, n (%) | |
| Male | 546 (61.1) |
| Female | 348 (38.9) |
| Age, mean (SD) | 54.93 (12.62) |
| Disease, n (%) | |
| Leukemia | 420 (47.0) |
| Lymphoma | 166 (18.6) |
| MDS/MPN | 199 (22.3) |
| Multiple myeloma | 93 (10.4) |
| Nonmalignant | 16 (1.8) |
| Intensity, n (%) | |
| Ablative | 589 (65.9) |
| Reduced intensity | 191 (21.4) |
| Nonablative | 114 (12.8) |
| Total body irradiation, n (%) | 273 (30.5) |
| Donor match, n (%) | |
| Related haploidentical | 44 (4.9) |
| Related identical | 288 (32.2) |
| Related nonidentical | 4 (0.4) |
| Unrelated identical | 447 (50.0) |
| Unrelated nonidentical | 111 (12.4) |
| Grafts, n (%) | |
| BM | 86 (9.6) |
| PBSCs, | 361 (40.4) |
| PBSCs, CD34+ | 447 (49.9) |
| GVHD (first 100 d), n (%) | 346 (39.8) |
| Grade 0-1 | 628 (70.2) |
| Grade 2-4 | 266 (29.8) |
| Lower gut GVHD | 84 (9.4) |
| Grade 0-1 | 855 (95.6) |
| Grade 2-4 | 39 (4.4) |
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; SD, standard deviation.